These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14760099)

  • 21. Caffeine enhances adriamycin antitumor activity in Ehrlich ascites carcinoma-bearing mice.
    Sadzuka Y; Mochizuki E; Iwazaki A; Hirota S; Takino Y
    Biol Pharm Bull; 1995 Jan; 18(1):159-61. PubMed ID: 7735232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Codelivery of doxorubicin-containing thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles enhances local cancer therapy.
    Sheu MT; Jhan HJ; Su CY; Chen LC; Chang CE; Liu DZ; Ho HO
    Colloids Surf B Biointerfaces; 2016 Jul; 143():260-270. PubMed ID: 27022865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
    Jackisch C; von Minckwitz G; Eidtmann H; Costa SD; Raab G; Blohmer JU; Schütte M; Gerber B; Merkle E; Gademann G; Lampe D; Hilfrich J; Tulusan AH; Caputo A; Kaufmann M
    Clin Breast Cancer; 2002 Oct; 3(4):276-80. PubMed ID: 12425756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caffeine modulates the antitumor activity and toxic side effects of adriamycin.
    Sadzuka Y; Mochizuki E; Takino Y
    Jpn J Cancer Res; 1993 Mar; 84(3):348-53. PubMed ID: 8486534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
    Garland LL; Hidalgo M; Mendelson DS; Ryan DP; Arun BK; Lovalvo JL; Eiseman IA; Olson SC; Lenehan PF; Eder JP
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4274-82. PubMed ID: 16857802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of docetaxel/doxorubicin combination in metastatic breast cancer.
    Diéras V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):31-3. PubMed ID: 9364539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma.
    Zheng D; Li X; Xu H; Lu X; Hu Y; Fan W
    Acta Biochim Biophys Sin (Shanghai); 2009 Jul; 41(7):578-87. PubMed ID: 19578721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.
    Ricevuto E; Cocciolone V; Mancini M; Cannita K; Romano S; Bruera G; Pelliccione M; Adinolfi MI; Ciccozzi A; Bafile A; Penco M; Ficorella C
    Oncologist; 2015 Feb; 20(2):109-10. PubMed ID: 25601964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
    Caffo O; Lo Re G; Sava T; Buti S; Sacco C; Basso U; Zustovich F; Lodde M; Perin A; Facchini G; Veccia A; Maines F; Barile C; Fratino L; Gernone A; De Vivo R; Pappagallo GL; Galligioni E
    Future Oncol; 2015; 11(6):965-73. PubMed ID: 25760977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination.
    Satoh M; Naganuma A; Imura N
    Cancer Chemother Pharmacol; 1988; 21(2):176-8. PubMed ID: 3349566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
    Schwartz GH; Jones CB; Garrison M; Patnaik A; Takimoto C; McCreery H; Skinner M; Tolcher AW; Rowinsky EK
    Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of docetaxel dosage in combination chemotherapy with carboplatin against advanced non-small cell lung cancer].
    Oyamada Y; Watanabe H; Fukunaga K; Nakamura H; Asano K; Hasegawa N; Yamaguchi K
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1917-22. PubMed ID: 14650959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Observation of the antitumor effect of endostar combined with docetaxel under different administration sequences].
    Yuan J; Wu CW; Liu ZJ; Wei XY; Li K
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):580-5. PubMed ID: 21122408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docetaxel in combination with doxorubicin: a phase I dose-finding study.
    Diéras V
    Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):17-20. PubMed ID: 9213322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
    Radaideh SM; Sledge GW
    Breast Cancer Res Treat; 2008 Sep; 111(2):203-8. PubMed ID: 17990102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.
    De Souza R; Zahedi P; Badame RM; Allen C; Piquette-Miller M
    Mol Cancer Ther; 2011 Jul; 10(7):1289-99. PubMed ID: 21551263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
    Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
    J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
    Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
    J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy.
    Wang P; Henning SM; Magyar CE; Elshimali Y; Heber D; Vadgama JV
    J Exp Clin Cancer Res; 2016 May; 35():73. PubMed ID: 27151407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.